This kit is used to detect hotspot mutations in exons 2, 3 and 4 of the human KRAS gene, hotspot mutations in exons 2, 3 and 4 of the human NRAS gene and hotspot mutations in exon 15 of the human BRAF gene. The kit uses DNA as the test sample to provide qualitative assessment of the mutation status, which provides a basis for clinicians to select tumor-targeted drug therapy for colorectal cancer patients.

Features: simple operation, easy to carry out; reliable results, intuitive interpretation; high sensitivity, sample saving.

Applicable samples: fresh tissue, frozen tissue, paraffin-embedded tissue, etc.

KRAS, NRAS, and BRAF are all signaling molecules downstream of EGFR and are key activators on numerous signaling pathways. Mutations in these genes are commonly found in a variety of malignant tumors, and the mutation rates in colorectal cancer patients are 20-50%, 1-6%, and 8-15%, respectively. mutations in KRAS, NRAS, and BRAF genes generally cause colorectal cancer patients to become resistant to anti-EGFR antibody-based drugs.

Therefore, the combined detection of KRAS/NRAS/BRAF gene mutations can improve the targeting of tumor clinical treatment, reduce the cost of treatment, and save valuable treatment time. It assists clinicians in screening out cancer patients with colorectal cancer and other cancers that can benefit from tumor-targeted drugs.